Evasion of Toll-like receptor 2 activation by staphylococcal superantigen-like protein 3

Toll-like receptors (TLRs) are crucial for our host defense against microbial infections. TLR2 is especially important to fight bacterial infections, as it specifically recognizes bacterial lipoproteins of both Gram-positive and Gram-negative origin. Present on a variety of immune cells, TLR2 is cri...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of molecular medicine (Berlin, Germany) Germany), 2012-10, Vol.90 (10), p.1109-1120
Hauptverfasser: Bardoel, B. W., Vos, R., Bouman, T., Aerts, P. C., Bestebroer, J., Huizinga, E. G., Brondijk, T. H. C., van Strijp, J. A. G., de Haas, C. J. C.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1120
container_issue 10
container_start_page 1109
container_title Journal of molecular medicine (Berlin, Germany)
container_volume 90
creator Bardoel, B. W.
Vos, R.
Bouman, T.
Aerts, P. C.
Bestebroer, J.
Huizinga, E. G.
Brondijk, T. H. C.
van Strijp, J. A. G.
de Haas, C. J. C.
description Toll-like receptors (TLRs) are crucial for our host defense against microbial infections. TLR2 is especially important to fight bacterial infections, as it specifically recognizes bacterial lipoproteins of both Gram-positive and Gram-negative origin. Present on a variety of immune cells, TLR2 is critical for host protection against several bacterial infections, including those caused by Staphylococcus aureus. This major human pathogen causes increasing health care problems due to its increased resistance to antibiotics. S. aureus secretes a wide variety of proteins that inhibit innate immune responses. Recently, several staphylococcal superantigen-like proteins (SSLs) have been described to mediate immune evasive properties. Here, we describe that SSL3 specifically binds and inhibits TLR2 activation on human and murine neutrophils and monocytes. Through binding of the extracellular TLR2 domain, SSL3 inhibits IL-8 production by HEK cells expressing TLR1/2 and TLR2/6 dimers, stimulated with their specific ligands. The SSL3–TLR2 interaction is partially glycan dependent as binding of SSL3 to TLR2 is affected upon removal of sialic acid residues. Moreover, the SSL3(R308A) mutant lacking glycan-binding properties shows lower TLR2 inhibition. An SSL3 mutant, lacking the N-terminal 126 amino acids, still retains full TLR2 inhibiting activity. Of other SSLs tested, only SSL4, which shares the highest homology with SSL3, blocks TLR2 activation. SSL3 is the first-described bacterial protein that blocks TLR2 activation through direct extracellular interaction with the receptor. This unique function of SSL3 adds to the arsenal of immune evasive molecules that S. aureus can employ to subvert both innate and adaptive immunity.
doi_str_mv 10.1007/s00109-012-0926-8
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1125225027</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1039202818</sourcerecordid><originalsourceid>FETCH-LOGICAL-c501t-832f036509eaa26dd2ac57d2a5b9f702419bfaca9cbbf4b0dc71864bb70e447c3</originalsourceid><addsrcrecordid>eNqF0d9r1TAUB_AgirtO_wBfRkEGvkRPTn41j2NsKgx8meBbSXLTrbO36ZJ2cP_7pfTqZCC-JJB8ck6SLyHvGXxiAPpzBmBgKDCkYFDR-gXZMMGRMiHgJdmAEYqiZuqIvMn5rmgtjXhNjrAsCiX4hvy8eLC5i0MV2-o69j3tu1-hSsGHcYqpwsr6qXuw00LcvsqTHW_3ffTRe9tXeR5DssPU3YRhPTmmOIVuqPhb8qq1fQ7vDvMx-XF5cX3-lV59__Lt_OyKeglsojXHFriSYIK1qLZbtF7qMkpnWg0omHGt9dZ451rhYOs1q5VwTkMQQnt-TD6udUvn-znkqdl12Ye-t0OIc24YQ4koAfX_KXCDgDWrC_3wjN7FOQ3lIYuqDdNcqqLYqnyKOafQNmPqdjbtC2qWhJo1oaYk1CwJNUvlk0Pl2e3C9s-J35EUcHoANpc_bsv_-i4_OcW51BqKw9XlsjXchPT3Ff_V_REUiad2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1038917356</pqid></control><display><type>article</type><title>Evasion of Toll-like receptor 2 activation by staphylococcal superantigen-like protein 3</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Bardoel, B. W. ; Vos, R. ; Bouman, T. ; Aerts, P. C. ; Bestebroer, J. ; Huizinga, E. G. ; Brondijk, T. H. C. ; van Strijp, J. A. G. ; de Haas, C. J. C.</creator><creatorcontrib>Bardoel, B. W. ; Vos, R. ; Bouman, T. ; Aerts, P. C. ; Bestebroer, J. ; Huizinga, E. G. ; Brondijk, T. H. C. ; van Strijp, J. A. G. ; de Haas, C. J. C.</creatorcontrib><description>Toll-like receptors (TLRs) are crucial for our host defense against microbial infections. TLR2 is especially important to fight bacterial infections, as it specifically recognizes bacterial lipoproteins of both Gram-positive and Gram-negative origin. Present on a variety of immune cells, TLR2 is critical for host protection against several bacterial infections, including those caused by Staphylococcus aureus. This major human pathogen causes increasing health care problems due to its increased resistance to antibiotics. S. aureus secretes a wide variety of proteins that inhibit innate immune responses. Recently, several staphylococcal superantigen-like proteins (SSLs) have been described to mediate immune evasive properties. Here, we describe that SSL3 specifically binds and inhibits TLR2 activation on human and murine neutrophils and monocytes. Through binding of the extracellular TLR2 domain, SSL3 inhibits IL-8 production by HEK cells expressing TLR1/2 and TLR2/6 dimers, stimulated with their specific ligands. The SSL3–TLR2 interaction is partially glycan dependent as binding of SSL3 to TLR2 is affected upon removal of sialic acid residues. Moreover, the SSL3(R308A) mutant lacking glycan-binding properties shows lower TLR2 inhibition. An SSL3 mutant, lacking the N-terminal 126 amino acids, still retains full TLR2 inhibiting activity. Of other SSLs tested, only SSL4, which shares the highest homology with SSL3, blocks TLR2 activation. SSL3 is the first-described bacterial protein that blocks TLR2 activation through direct extracellular interaction with the receptor. This unique function of SSL3 adds to the arsenal of immune evasive molecules that S. aureus can employ to subvert both innate and adaptive immunity.</description><identifier>ISSN: 0946-2716</identifier><identifier>EISSN: 1432-1440</identifier><identifier>DOI: 10.1007/s00109-012-0926-8</identifier><identifier>PMID: 22714643</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Adaptive Immunity ; Animals ; Antigens, Bacterial - immunology ; Antigens, Bacterial - pharmacology ; Antigens, CD - metabolism ; Bacterial diseases ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; General aspects ; Glycosylation ; HEK293 Cells ; Host-Pathogen Interactions ; Human bacterial diseases ; Human Genetics ; Humans ; Immune Evasion ; Immunity, Innate ; Indexing in process ; Infectious diseases ; Interleukin-8 - biosynthesis ; Interleukin-8 - secretion ; Internal Medicine ; Medical sciences ; Mice ; Molecular Medicine ; Monocytes - immunology ; Monocytes - metabolism ; Monocytes - secretion ; Neutrophils - immunology ; Neutrophils - metabolism ; Neutrophils - secretion ; Original Article ; Protein Binding ; Sialic Acids - metabolism ; Staphylococcal infections, streptococcal infections, pneumococcal infections ; Staphylococcus aureus - immunology ; Staphylococcus aureus - physiology ; Superantigens - immunology ; Superantigens - pharmacology ; Toll-Like Receptor 2 - antagonists &amp; inhibitors ; Toll-Like Receptor 2 - metabolism ; Tumor Necrosis Factor-alpha - biosynthesis ; Tumor Necrosis Factor-alpha - secretion</subject><ispartof>Journal of molecular medicine (Berlin, Germany), 2012-10, Vol.90 (10), p.1109-1120</ispartof><rights>Springer-Verlag 2012</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c501t-832f036509eaa26dd2ac57d2a5b9f702419bfaca9cbbf4b0dc71864bb70e447c3</citedby><cites>FETCH-LOGICAL-c501t-832f036509eaa26dd2ac57d2a5b9f702419bfaca9cbbf4b0dc71864bb70e447c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00109-012-0926-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00109-012-0926-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,781,785,27929,27930,41493,42562,51324</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=26335770$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22714643$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bardoel, B. W.</creatorcontrib><creatorcontrib>Vos, R.</creatorcontrib><creatorcontrib>Bouman, T.</creatorcontrib><creatorcontrib>Aerts, P. C.</creatorcontrib><creatorcontrib>Bestebroer, J.</creatorcontrib><creatorcontrib>Huizinga, E. G.</creatorcontrib><creatorcontrib>Brondijk, T. H. C.</creatorcontrib><creatorcontrib>van Strijp, J. A. G.</creatorcontrib><creatorcontrib>de Haas, C. J. C.</creatorcontrib><title>Evasion of Toll-like receptor 2 activation by staphylococcal superantigen-like protein 3</title><title>Journal of molecular medicine (Berlin, Germany)</title><addtitle>J Mol Med</addtitle><addtitle>J Mol Med (Berl)</addtitle><description>Toll-like receptors (TLRs) are crucial for our host defense against microbial infections. TLR2 is especially important to fight bacterial infections, as it specifically recognizes bacterial lipoproteins of both Gram-positive and Gram-negative origin. Present on a variety of immune cells, TLR2 is critical for host protection against several bacterial infections, including those caused by Staphylococcus aureus. This major human pathogen causes increasing health care problems due to its increased resistance to antibiotics. S. aureus secretes a wide variety of proteins that inhibit innate immune responses. Recently, several staphylococcal superantigen-like proteins (SSLs) have been described to mediate immune evasive properties. Here, we describe that SSL3 specifically binds and inhibits TLR2 activation on human and murine neutrophils and monocytes. Through binding of the extracellular TLR2 domain, SSL3 inhibits IL-8 production by HEK cells expressing TLR1/2 and TLR2/6 dimers, stimulated with their specific ligands. The SSL3–TLR2 interaction is partially glycan dependent as binding of SSL3 to TLR2 is affected upon removal of sialic acid residues. Moreover, the SSL3(R308A) mutant lacking glycan-binding properties shows lower TLR2 inhibition. An SSL3 mutant, lacking the N-terminal 126 amino acids, still retains full TLR2 inhibiting activity. Of other SSLs tested, only SSL4, which shares the highest homology with SSL3, blocks TLR2 activation. SSL3 is the first-described bacterial protein that blocks TLR2 activation through direct extracellular interaction with the receptor. This unique function of SSL3 adds to the arsenal of immune evasive molecules that S. aureus can employ to subvert both innate and adaptive immunity.</description><subject>Adaptive Immunity</subject><subject>Animals</subject><subject>Antigens, Bacterial - immunology</subject><subject>Antigens, Bacterial - pharmacology</subject><subject>Antigens, CD - metabolism</subject><subject>Bacterial diseases</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>General aspects</subject><subject>Glycosylation</subject><subject>HEK293 Cells</subject><subject>Host-Pathogen Interactions</subject><subject>Human bacterial diseases</subject><subject>Human Genetics</subject><subject>Humans</subject><subject>Immune Evasion</subject><subject>Immunity, Innate</subject><subject>Indexing in process</subject><subject>Infectious diseases</subject><subject>Interleukin-8 - biosynthesis</subject><subject>Interleukin-8 - secretion</subject><subject>Internal Medicine</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Molecular Medicine</subject><subject>Monocytes - immunology</subject><subject>Monocytes - metabolism</subject><subject>Monocytes - secretion</subject><subject>Neutrophils - immunology</subject><subject>Neutrophils - metabolism</subject><subject>Neutrophils - secretion</subject><subject>Original Article</subject><subject>Protein Binding</subject><subject>Sialic Acids - metabolism</subject><subject>Staphylococcal infections, streptococcal infections, pneumococcal infections</subject><subject>Staphylococcus aureus - immunology</subject><subject>Staphylococcus aureus - physiology</subject><subject>Superantigens - immunology</subject><subject>Superantigens - pharmacology</subject><subject>Toll-Like Receptor 2 - antagonists &amp; inhibitors</subject><subject>Toll-Like Receptor 2 - metabolism</subject><subject>Tumor Necrosis Factor-alpha - biosynthesis</subject><subject>Tumor Necrosis Factor-alpha - secretion</subject><issn>0946-2716</issn><issn>1432-1440</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqF0d9r1TAUB_AgirtO_wBfRkEGvkRPTn41j2NsKgx8meBbSXLTrbO36ZJ2cP_7pfTqZCC-JJB8ck6SLyHvGXxiAPpzBmBgKDCkYFDR-gXZMMGRMiHgJdmAEYqiZuqIvMn5rmgtjXhNjrAsCiX4hvy8eLC5i0MV2-o69j3tu1-hSsGHcYqpwsr6qXuw00LcvsqTHW_3ffTRe9tXeR5DssPU3YRhPTmmOIVuqPhb8qq1fQ7vDvMx-XF5cX3-lV59__Lt_OyKeglsojXHFriSYIK1qLZbtF7qMkpnWg0omHGt9dZ451rhYOs1q5VwTkMQQnt-TD6udUvn-znkqdl12Ye-t0OIc24YQ4koAfX_KXCDgDWrC_3wjN7FOQ3lIYuqDdNcqqLYqnyKOafQNmPqdjbtC2qWhJo1oaYk1CwJNUvlk0Pl2e3C9s-J35EUcHoANpc_bsv_-i4_OcW51BqKw9XlsjXchPT3Ff_V_REUiad2</recordid><startdate>20121001</startdate><enddate>20121001</enddate><creator>Bardoel, B. W.</creator><creator>Vos, R.</creator><creator>Bouman, T.</creator><creator>Aerts, P. C.</creator><creator>Bestebroer, J.</creator><creator>Huizinga, E. G.</creator><creator>Brondijk, T. H. C.</creator><creator>van Strijp, J. A. G.</creator><creator>de Haas, C. J. C.</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>7QL</scope><scope>C1K</scope></search><sort><creationdate>20121001</creationdate><title>Evasion of Toll-like receptor 2 activation by staphylococcal superantigen-like protein 3</title><author>Bardoel, B. W. ; Vos, R. ; Bouman, T. ; Aerts, P. C. ; Bestebroer, J. ; Huizinga, E. G. ; Brondijk, T. H. C. ; van Strijp, J. A. G. ; de Haas, C. J. C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c501t-832f036509eaa26dd2ac57d2a5b9f702419bfaca9cbbf4b0dc71864bb70e447c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adaptive Immunity</topic><topic>Animals</topic><topic>Antigens, Bacterial - immunology</topic><topic>Antigens, Bacterial - pharmacology</topic><topic>Antigens, CD - metabolism</topic><topic>Bacterial diseases</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>General aspects</topic><topic>Glycosylation</topic><topic>HEK293 Cells</topic><topic>Host-Pathogen Interactions</topic><topic>Human bacterial diseases</topic><topic>Human Genetics</topic><topic>Humans</topic><topic>Immune Evasion</topic><topic>Immunity, Innate</topic><topic>Indexing in process</topic><topic>Infectious diseases</topic><topic>Interleukin-8 - biosynthesis</topic><topic>Interleukin-8 - secretion</topic><topic>Internal Medicine</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Molecular Medicine</topic><topic>Monocytes - immunology</topic><topic>Monocytes - metabolism</topic><topic>Monocytes - secretion</topic><topic>Neutrophils - immunology</topic><topic>Neutrophils - metabolism</topic><topic>Neutrophils - secretion</topic><topic>Original Article</topic><topic>Protein Binding</topic><topic>Sialic Acids - metabolism</topic><topic>Staphylococcal infections, streptococcal infections, pneumococcal infections</topic><topic>Staphylococcus aureus - immunology</topic><topic>Staphylococcus aureus - physiology</topic><topic>Superantigens - immunology</topic><topic>Superantigens - pharmacology</topic><topic>Toll-Like Receptor 2 - antagonists &amp; inhibitors</topic><topic>Toll-Like Receptor 2 - metabolism</topic><topic>Tumor Necrosis Factor-alpha - biosynthesis</topic><topic>Tumor Necrosis Factor-alpha - secretion</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bardoel, B. W.</creatorcontrib><creatorcontrib>Vos, R.</creatorcontrib><creatorcontrib>Bouman, T.</creatorcontrib><creatorcontrib>Aerts, P. C.</creatorcontrib><creatorcontrib>Bestebroer, J.</creatorcontrib><creatorcontrib>Huizinga, E. G.</creatorcontrib><creatorcontrib>Brondijk, T. H. C.</creatorcontrib><creatorcontrib>van Strijp, J. A. G.</creatorcontrib><creatorcontrib>de Haas, C. J. C.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Journal of molecular medicine (Berlin, Germany)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bardoel, B. W.</au><au>Vos, R.</au><au>Bouman, T.</au><au>Aerts, P. C.</au><au>Bestebroer, J.</au><au>Huizinga, E. G.</au><au>Brondijk, T. H. C.</au><au>van Strijp, J. A. G.</au><au>de Haas, C. J. C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evasion of Toll-like receptor 2 activation by staphylococcal superantigen-like protein 3</atitle><jtitle>Journal of molecular medicine (Berlin, Germany)</jtitle><stitle>J Mol Med</stitle><addtitle>J Mol Med (Berl)</addtitle><date>2012-10-01</date><risdate>2012</risdate><volume>90</volume><issue>10</issue><spage>1109</spage><epage>1120</epage><pages>1109-1120</pages><issn>0946-2716</issn><eissn>1432-1440</eissn><abstract>Toll-like receptors (TLRs) are crucial for our host defense against microbial infections. TLR2 is especially important to fight bacterial infections, as it specifically recognizes bacterial lipoproteins of both Gram-positive and Gram-negative origin. Present on a variety of immune cells, TLR2 is critical for host protection against several bacterial infections, including those caused by Staphylococcus aureus. This major human pathogen causes increasing health care problems due to its increased resistance to antibiotics. S. aureus secretes a wide variety of proteins that inhibit innate immune responses. Recently, several staphylococcal superantigen-like proteins (SSLs) have been described to mediate immune evasive properties. Here, we describe that SSL3 specifically binds and inhibits TLR2 activation on human and murine neutrophils and monocytes. Through binding of the extracellular TLR2 domain, SSL3 inhibits IL-8 production by HEK cells expressing TLR1/2 and TLR2/6 dimers, stimulated with their specific ligands. The SSL3–TLR2 interaction is partially glycan dependent as binding of SSL3 to TLR2 is affected upon removal of sialic acid residues. Moreover, the SSL3(R308A) mutant lacking glycan-binding properties shows lower TLR2 inhibition. An SSL3 mutant, lacking the N-terminal 126 amino acids, still retains full TLR2 inhibiting activity. Of other SSLs tested, only SSL4, which shares the highest homology with SSL3, blocks TLR2 activation. SSL3 is the first-described bacterial protein that blocks TLR2 activation through direct extracellular interaction with the receptor. This unique function of SSL3 adds to the arsenal of immune evasive molecules that S. aureus can employ to subvert both innate and adaptive immunity.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>22714643</pmid><doi>10.1007/s00109-012-0926-8</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0946-2716
ispartof Journal of molecular medicine (Berlin, Germany), 2012-10, Vol.90 (10), p.1109-1120
issn 0946-2716
1432-1440
language eng
recordid cdi_proquest_miscellaneous_1125225027
source MEDLINE; SpringerNature Journals
subjects Adaptive Immunity
Animals
Antigens, Bacterial - immunology
Antigens, Bacterial - pharmacology
Antigens, CD - metabolism
Bacterial diseases
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
General aspects
Glycosylation
HEK293 Cells
Host-Pathogen Interactions
Human bacterial diseases
Human Genetics
Humans
Immune Evasion
Immunity, Innate
Indexing in process
Infectious diseases
Interleukin-8 - biosynthesis
Interleukin-8 - secretion
Internal Medicine
Medical sciences
Mice
Molecular Medicine
Monocytes - immunology
Monocytes - metabolism
Monocytes - secretion
Neutrophils - immunology
Neutrophils - metabolism
Neutrophils - secretion
Original Article
Protein Binding
Sialic Acids - metabolism
Staphylococcal infections, streptococcal infections, pneumococcal infections
Staphylococcus aureus - immunology
Staphylococcus aureus - physiology
Superantigens - immunology
Superantigens - pharmacology
Toll-Like Receptor 2 - antagonists & inhibitors
Toll-Like Receptor 2 - metabolism
Tumor Necrosis Factor-alpha - biosynthesis
Tumor Necrosis Factor-alpha - secretion
title Evasion of Toll-like receptor 2 activation by staphylococcal superantigen-like protein 3
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T08%3A38%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evasion%20of%20Toll-like%20receptor%202%20activation%20by%20staphylococcal%20superantigen-like%20protein%203&rft.jtitle=Journal%20of%20molecular%20medicine%20(Berlin,%20Germany)&rft.au=Bardoel,%20B.%20W.&rft.date=2012-10-01&rft.volume=90&rft.issue=10&rft.spage=1109&rft.epage=1120&rft.pages=1109-1120&rft.issn=0946-2716&rft.eissn=1432-1440&rft_id=info:doi/10.1007/s00109-012-0926-8&rft_dat=%3Cproquest_cross%3E1039202818%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1038917356&rft_id=info:pmid/22714643&rfr_iscdi=true